Skip to main content

BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering

Immix Biopharma (NASDAQ: IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at $2.71 per share. Gross proceeds from the offering to ImmixBio are projected to be an estimated $15 million, before standard deductions and expenses. According to the announcement, ImmixBio plans to use funds from the offering for its NXC-201 clinical trials as well as working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.

To view the full press release, visit

About Immix Biopharma Inc.

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies in autoimmune disease. The company’s lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, currently being evaluated in an ongoing phase 1b/2a NEXICART-1 (NCT04720313) clinical trial. For more information about the company, visit

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.